Roisin E. O’Cearbhaill

Jan 8, 2025 | nature.com | Jyoti S. Mayadev |Dmitriy Zamarin |Heather A. Lankes |Barbara L. Banbury |Cara Mathews |David M. O’Malley | +1 more

AbstractCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.

Jul 27, 2023 | nature.com | Raffit Hassan |Marcus Butler |Roisin E. O’Cearbhaill |Melissa Johnson |Nirali Shah |Babak Saboury | +2 more

AbstractThe T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results from an ongoing phase1/2 trial of gavo-cel in patients with treatment-refractory mesothelin-expressing solid tumors.